Biologicals_BeiGene_NDA_China

Boehringer Ingelheim Biopharmaceuticals China supports BeiGene in its China NDA submission of anti-PD-1 antibody, tislelizumabFirst biologic manufactured by Boehringer Ingelheim BioChina accepted for New Drug Application reviewImportant milestone for Boehringer Ingelheims ’ collaboration partner BeiGene in immuno-oncologyBoehringer Ingelheim BioChina is proud to support BeiGene in serving patients worldwide with this important medicine  
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news